Vir Biotechnology (VIR) Stock Price
Vir Biotechnology Price
Over the last 8 years Vir Biotechnology grew revenue by 49.8% annually, reaching 68.56 M USD. For Vir Biotechnology, the net margin of -638.9% is down versus 48.3% a few years ago. The consensus 12-month price target for Vir Biotechnology is 20.00 USD, about 120.3% above where the stock trades today. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.
Vir Biotechnology stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Vir Biotechnology business model & stock analysis
Frequently asked questions about Vir Biotechnology
Vir Biotechnology Inc's business model is focused on developing novel therapies to combat serious infectious diseases. The company utilizes cutting-edge technologies and a deep understanding of the immune system to develop treatments for viral infections. Vir Biotechnology aims to address unmet medical needs by harnessing the power of antiviral antibodies and other approaches to provide innovative solutions. With a strong pipeline and strategic partnerships, Vir Biotechnology is dedicated to advancing breakthrough therapies to improve global public health.
Vir Biotechnology Inc is primarily active in the biotechnology industry.
Vir Biotechnology Inc has several main competitors in the market. Some of the notable competitors of Vir Biotechnology Inc include Gilead Sciences Inc, Moderna Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the field of biotechnology and pharmaceuticals, specializing in developing innovative therapies, treatments, and vaccines. With their focus on advancing biomedical research and developing breakthrough solutions, the competitive landscape for Vir Biotechnology Inc remains intense. However, Vir Biotechnology Inc strives to stay at the forefront of the industry by leveraging its expertise and partnerships to address global health challenges and deliver value to its stakeholders.
Vir Biotechnology Inc. is a renowned company with an impressive history and background. Founded in 2016, Vir Biotechnology is a clinical-stage immunology company focused on developing therapeutic solutions for severe infectious diseases. The company is committed to utilizing cutting-edge technologies to address global health challenges. Vir Biotechnology has established strategic partnerships with world-leading institutions and has a diverse portfolio of innovative treatments. With its relentless dedication to scientific excellence and unwavering commitment to public health, Vir Biotechnology Inc. has gained significant recognition and continues to be at the forefront of advancing breakthrough treatments for infectious diseases worldwide.
Vir Biotechnology Inc has achieved several significant milestones in its journey. The company successfully completed its initial public offering (IPO) in October 2019, raising substantial capital to support its research and development efforts. Vir Biotechnology has also formed multiple strategic collaborations with renowned pharmaceutical companies, including Gilead Sciences and GlaxoSmithKline, to advance its pipeline of innovative therapies. Furthermore, Vir Biotechnology received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential therapy for hepatitis B virus infection. These accomplishments demonstrate Vir Biotechnology's commitment to progress and innovation in the field of biotechnology.
Vir Biotechnology Inc is primarily present in the United States.
Vir Biotechnology Inc is a leading biotechnology company with a strong focus on innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and a commitment to improving patient health. Vir Biotechnology Inc believes in leveraging cutting-edge technologies to develop novel therapeutic solutions for the most challenging infectious diseases. With a mission to address global health concerns, the company combines its extensive expertise in immunology and infectious diseases to create transformative treatments and preventive measures. Vir Biotechnology Inc's corporate philosophy centers around the belief that every patient deserves access to safe and effective therapies.
Analysts currently set an average price target of 21.43 USD for the Vir Biotechnology stock (median: 20.00 USD), implying +141.6 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Vir Biotechnology stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Vir Biotechnology to generate revenue of 330.33 M USD and earnings per share of -1.14 USD.
Converted at the current exchange rate, the Vir Biotechnology share trades at 8.27 EUR (9.08 USD).
The Vir Biotechnology share (VIR) is listed on 1 stock exchanges, including: NASDAQ (VIR).
Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions. Vir Biotechnology Inc. is a young biopharmaceutical company that focuses on combating infectious diseases. The company relies on a combination of scientific expertise, innovative technologies, and extensive partnerships to develop advanced therapies and vaccines against some of the world's most dangerous viruses. The company specializes in three main areas: infectious diseases, immunology, and oncology. In the field of infectious diseases, Vir Biotechnology focuses on developing drugs for serious viral infections such as HIV, hepatitis B, cytomegalovirus, and influenza. In the field of immunology, the company explores the mechanisms underlying the immune system to find new ways to treat autoimmune and inflammatory diseases. Additionally, Vir is working on developing cancer immunotherapies and personalized therapy approaches for the fight against cancer. The company works closely with a range of partners, including universities, research institutions, and biopharmaceutical companies. In 2020, Vir entered into a collaboration agreement with biotechnology company GSK to jointly develop antibodies against COVID-19. A key part of Vir Biotechnology's business model is research and development of new therapies and vaccines. The company heavily invests in its research facilities in San Francisco, California and Cambridge, United Kingdom to develop new technologies and solutions. Vir has already brought several products to market, including a new antibody preparation for the treatment of influenza and a personalized immunotherapy for cancer. Additionally, the company aims to develop a variety of products and technologies to combat infectious diseases, including viral vectors, RNA- and DNA-based therapies, and new immunotherapies. Vir Biotechnology's business model also includes a strong capital raising strategy. The company has already completed several funding rounds and successfully gone public to support its growth and advancement. In summary, Vir Biotechnology is an innovative biopharmaceutical company that is developing a wide range of products and technologies to combat infectious diseases, autoimmune diseases, and cancer. The company relies on scientific expertise, partnerships, and a strong capital raising strategy to promote the growth and development of its business. With a dedicated focus on research and development and a strong pipeline of products and therapies, Vir Biotechnology remains a key player in the fight against infectious diseases and other serious conditions.
The expected revenue of Vir Biotechnology is 330.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Vir Biotechnology is -158.97 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Vir Biotechnology is currently -7.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vir Biotechnology stock.
The price-to-sales ratio (P/S) of Vir Biotechnology is currently 3.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vir Biotechnology stock.
The Eulerpool Quality Score for Vir Biotechnology is 2/10.
The ISIN of Vir Biotechnology is US92764N1028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Vir Biotechnology is A2PS0P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Vir Biotechnology is VIR. The ticker symbol is used to trade Vir Biotechnology shares on the stock exchange.
Vir Biotechnology stock
Vir Biotechnology Peer Group
Vir Biotechnology Ticker
Vir Biotechnology FIGI
All fundamentals and in-depth analysis of Vir Biotechnology
Our stock analysis for Vir Biotechnology stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vir Biotechnology. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.